Physician profile
Patrick M Mceldrew
NPI 1568490415
$791.55
in general payments reported to CMS, 2019-2025
11 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $48.19 · 2021: $39.66 · 2023: $48.21 · 2024: $151 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $255.69 | 2025 | Renasys Go V2 Home, Grafix |
| Organogenesis INC. | $169.88 | 2019-2021 | |
| Convatec INC. | $90.53 | 2021-2025 | |
| Urgo Medical North America, LLC | $75.32 | 2024-2025 | Urgok2 |
| Mimedx Group, INC. | $42.87 | 2024 | |
| Kci USA, INC. | $42.64 | 2020-2023 | Promogran Prisma, V.A.C. Dermatac, Activ.A.C. |
| Integra Lifesciences Corporation | $39.99 | 2024-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Abbvie INC. | $30.78 | 2023-2025 | |
| Aroa Biosurgery Incorporated | $16.57 | 2019 | |
| Kerecis Limited | $13.68 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Janssen Pharmaceuticals, INC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mceldrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.